Business Context and Reporting Period
Puma Biotechnology, Inc. (PBYI) filed this Form 8-K on July 23, 2021, to report the entry into a material definitive agreement and the creation of a direct financial obligation. The Company is a biotechnology firm focused on the development and commercialization of NERLYNX.
Key Financial Metrics and Transaction Details
- New Debt Issuance: The Company issued notes with an aggregate principal amount of $100.0 million under a Note Purchase Agreement with Athyrium Opportunities IV Co-Invest 1 LP and affiliates.
- Debt Repayment: Proceeds from the new notes, combined with cash on hand, were used to repay $100 million outstanding under a prior credit facility, plus approximately $9.2 million in accrued interest, exit fees, prepayment fees, and legal fees.
- Interest Rate: Notes bear interest at 8.0% plus Adjusted Three-Month LIBOR.
- Collateral: Obligations are secured by substantially all Company assets, including intellectual property, and a pledge of 65% of the issued and outstanding capital stock of its subsidiaries (Puma Biotechnology Ltd. and Puma Biotechnology B.V.).
- Available Capacity: Subject to conditions, an additional $25.0 million in notes remains available under the agreement.
Material Changes and Terms
The primary material change is the refinancing of the Company's debt structure. The new facility replaces the prior credit facility with a secured note structure featuring specific amortization and maturity terms:
- Amortization: Quarterly principal payments commence on June 30, 2024 (the "Amortization Date").
- Maturity: All unpaid principal and accrued interest are due in full on July 23, 2026.
- Prepayment and Exit Fees: Prepayment prior to the second anniversary incurs a make-whole amount; prepayment between the second and third anniversary incurs a 2.0% fee. An exit fee of 2.00% of the aggregate principal amount is required upon any prepayment or repayment.
Covenants, Risks, and Contingencies
The Note Purchase Agreement imposes significant affirmative and negative covenants that restrict the Company's operational flexibility:
- Affirmative Covenants: The Company must maintain a minimum amount of unrestricted cash in deposit accounts subject to a control agreement and achieve a specified minimum revenue threshold based on NERLYNX sales (U.S. sales and international royalties) measured over four consecutive fiscal quarters.
- Negative Covenants: Restrictions include limitations on incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends, making investments, creating liens, selling assets, and suffering a change in control.
- Events of Default: Defaults include failure to pay principal or interest, covenant breaches, insolvency, material adverse changes, or judgments exceeding $750,000. Default triggers a 2.0% interest rate penalty and allows the administrative agent to exercise remedies, including foreclosure on collateral and cash.
Investor Verification Checklist
- Verify the Company's current unrestricted cash balance against the minimum threshold required by the new control agreement.
- Monitor quarterly NERLYNX sales and royalty revenue to ensure compliance with the specified minimum revenue covenants.
- Review the Company's liquidity position given the requirement to make quarterly interest payments and the upcoming principal amortization starting June 30, 2024.
- Assess the impact of the 2.0% exit fee and potential make-whole provisions on future refinancing or prepayment strategies.
- Confirm that no additional indebtedness or restricted transactions have occurred that would breach the negative covenants.